A cell surface-displayed anti-c-myc single-chain antibody: new perspectives for the genetic improvement of cellular tumor vaccines.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9432230 Publication Model: Print Cited Medium: Print ISSN: 0929-1903 (Print) Linking ISSN: 09291903 NLM ISO Abbreviation: Cancer Gene Ther Subsets: MEDLINE
    • Publication Information:
      Publication: <2002->: London : Nature Publishing Group
      Original Publication: Norwalk, CT : Appleton & Lange, c1994-
    • Subject Terms:
      Antibodies, Monoclonal/*immunology ; Antigens, Surface/*immunology ; Cancer Vaccines/*therapeutic use ; Genes, myc/*immunology ; Immunoglobulin Fragments/*immunology ; Lymphocyte Activation/*immunology ; T-Lymphocytes/*immunology; Binding Sites ; Cell Division/drug effects ; DNA Primers/chemistry ; Flow Cytometry ; Fluorescent Antibody Technique ; Gene Expression ; Genes, myc/genetics ; Genetic Vectors ; Humans ; Immunogenetics ; Interferon-gamma/analysis ; Interleukin-4/analysis ; Polymerase Chain Reaction ; Proto-Oncogene Mas ; Tumor Cells, Cultured/drug effects
    • Abstract:
      We have shown recently that cell surface-bound, single-chain Fv antibodies (scFv) are a powerful tool for the improvement of cellular tumor vaccines. To simplify this approach and to develop a general tool for the generation and improvement of cellular tumor vaccines, we chose an scFv against a peptide from the human proto-oncogene c-myc that could anchor any c-myc-tagged protein to the cell surface. The retroviral vector p50-Mx-neo (pMESV) was used to express scFv on the surface of the human melanoma line SkMel63. The cell-bound anti-c-myc scFv bound specifically to a soluble purified anti-CD28 scFv carrying a c-myc peptide-tag at its C terminus. Proof of principle was determined by incubating human peripheral blood lymphocytes with a mixture of (a) anti-c-myc-transfected SkMel63 cells binding the anti-CD28 scFv and (b) SkMel63 cells transfected with an anti-CD3 scFv. A clear synergistic effect on T-cell activation was observed that was comparable with that obtained in previous studies using SkMel63 cells transfected with the gene for the anti-CD28 scFv. As the cell surface-displayed anti-c-myc scFv can bind any c-myc-tagged protein of interest, this technique facilitates the genetic engineering of cellular vaccines for the therapy of virtually all human neoplasias.
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (Antigens, Surface)
      0 (Cancer Vaccines)
      0 (DNA Primers)
      0 (Immunoglobulin Fragments)
      0 (MAS1 protein, human)
      0 (Proto-Oncogene Mas)
      207137-56-2 (Interleukin-4)
      82115-62-6 (Interferon-gamma)
    • Publication Date:
      Date Created: 20001007 Date Completed: 20010125 Latest Revision: 20211203
    • Publication Date:
      20231215
    • Accession Number:
      10.1038/sj.cgt.7700230
    • Accession Number:
      11023198